Author

R. Valdez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 9 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 11 Organism:human· 9 Assay:proteomics· 5 Organism:virus· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Gordon· 11 shared D. D. Ho· 11 shared Q. Wang· 11 shared L. Liu· 8 shared Y. Guo· 8 shared I. A. Mellis· 5 shared A. Bowen· 3 shared A. S. Lauring· 3 shared

Activity by Year

2022-2024 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersMicrobiology

A. Gordon

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

SARS-CoV-2 Omicron BA.2.87.1 Exhibits Higher Susceptibility to Serum Neutralization Than EG.5.1 and JN.1

Q. Wang, Y. Guo, L. T. Schwanz, I. A. Mellis, Y. Sun, Y. Qu, G. Urtecho, R. Valdez, E. Stoneman, A. Gordon, H. H. Wang, L. Liu, D. D. Ho

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

bioRxiv · Mar 10, 2024Microbiology

Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster

Q. Wang, I. A. Mellis, Y. Guo, C. Gherasim, R. Valdez, A. Gordon, L. Liu, D. D. Ho

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

bioRxiv · Feb 16, 2024 · PreprintImmunology

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants

Q. Wang, Y. Guo, A. Bowen, I. A. Mellis, R. Valdez, C. Gherasim, A. Gordon, L. Liu, D. D. Ho

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

bioRxiv · Nov 26, 2023 · PreprintImmunology

Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike

Q. Wang, Y. Guo, L. Liu, L. T. Schwanz, Z. Li, J. Ho, R. M. Zhang, S. Iketani, J. Yu, Y. Huang, Y. Qu, R. Valdez, A. S. Lauring, A. Gordon, H. H. Wang, , D. D. Ho

This paper evaluates the antigenicity and receptor affinity of the SARS-CoV-2 BA.2.86 subvariant, finding it not more resistant to human sera than other variants but with specific mAb resistance and high receptor affinity.

bioRxiv · Sep 24, 2023Microbiology

Antibody Neutralization of Emerging SARS-CoV-2: EG.5.1 and XBC.1.6

Q. Wang, Y. Guo, R. M. Zhang, J. Ho, H. Mohri, R. Valdez, D. M. Manthei, A. Gordon, L. Liu, D. D. Ho

This study evaluates antibody neutralization resistance of SARS-CoV-2 variants EG.5.1 and XBC.1.6 using pseudovirus assays and sera/mAbs, finding distinct evasion profiles and suggesting immunological imprinting and non-evasion-driven prevalence.

bioRxiv · Aug 21, 2023 · PreprintMicrobiology

SARS-CoV-2 Neutralizing Antibodies Following a Second BA.5 Bivalent Booster

Q. Wang, A. Bowen, J. Ho, R. Zhang, R. Valdez, E. Stoneman, A. Gordon, L. Lihong, D. D. Ho

This study evaluates the effect of a second BA.5 bivalent booster on SARS-CoV-2 neutralizing antibodies in elderly individuals, finding no significant increase in Omicron-specific titers after the second dose.

bioRxiv · Aug 13, 2023 · PreprintMicrobiology

Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine

Q. Wang, Y. Guo, A. R. Tam, R. Valdez, A. Gordon, L. Lihong, D. D. Ho

This study shows that the ancestral spike in bivalent COVID-19 vaccines causes deep immunological imprinting, limiting antibody breadth against Omicron subvariants.

bioRxiv · May 3, 2023Microbiology

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2

Q. Wang, Z. Li, Y. Guo, I. A. Mellis, S. Iketani, M. Liu, J. Yu, R. Valdez, A. S. Lauring, Z. Sheng, A. Gordon, L. Liu, D. D. Ho

The paper analyzes the receptor affinity and antibody evasion properties of SARS-CoV-2 BA.2.75 subvariants, identifying two evolutionary pathways and three mutations that influence their virological features.

bioRxiv · Mar 22, 2023Microbiology

SARS-CoV-2 Neutralizing Antibodies After Bivalent vs. Monovalent Booster

Q. Wang, A. D. Bowen, A. R. Tam, R. Valdez, E. Stoneman, I. A. Mellis, A. Gordon, L. Liu, D. D. Ho

This study compares neutralizing antibody titers after bivalent and monovalent mRNA boosters and BA.5 breakthrough infection, finding no significant difference at one month but higher titers in breakthrough patients at three months.

bioRxiv · Feb 13, 2023 · PreprintMicrobiology

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Q. Wang, S. Iketani, Z. Li, L. Liu, Y. Guo, Y. Huang, A. D. Bowen, M. Liu, M. Wang, J. Yu, R. Valdez, A. S. Lauring, Z. Sheng, H. H. Wang, A. Gordon, , D. D. Ho

This study shows that new SARS-CoV-2 BQ and XBB subvariants have significantly reduced neutralization by vaccines and monoclonal antibodies, suggesting a threat to current immunity.

bioRxiv · Nov 23, 2022Microbiology

Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot

Q. Wang, A. Bowen, R. Valdez, C. Gherasim, A. Gordon, L. Lihong, D. D. Ho

This study compares neutralizing antibody responses to bivalent and monovalent mRNA vaccines against SARS-CoV-2 variants, finding similar titers for bivalent vaccines against Omicron BA.4/BA.5 and ancestral strains.

bioRxiv · Oct 22, 2022 · PreprintMicrobiology